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ABSTRACT
To evaluate the clinical characteristics of invasive aspergillosis (IA) after reduced-intensity stem cell trans-
plantation (RIST) compared with those after conventional stem cell transplantation (CST), we examined the
medical records of 486 CST and 178 RIST recipients. The overall incidence of IA after allogeneic transplan-
tation was 35 (5.3%) of 664, which gave a 3-year cumulative incidence of 5.6%. The estimated 3-year incidence
of IA in CST and RIST was 4.5% and 8.2% (P  .045), respectively, but the mortality rates were similar (76%
and 86%). The median onset of IA after RIST (day 127) occurred significantly later than that after CST (day
97). A multivariate analysis revealed that IA was associated with age older than 50 years (relative risk, 2.12; 95%
confidence interval, 1.08-4.17; P .03) and the presence of acute and/or chronic GVHD (relative risk, 6.2; 95%
confidence interval, 2.4-16.4; P  .0002). IA remains an important complication after allogeneic transplanta-
tion, regardless of the type of conditioning regimen.
© 2004 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Over the past few decades, many changes in trans-
lantation strategies and supportive measures have
een developed, and these may inﬂuence the epide-
iology of fungal infection. Since prophylactic use of
uconazole for the prevention of candida infection has
ecome a common practice in allogeneic hematopoi-
tic stem cell transplantation (HSCT), candida and
olds that are resistant to azoles have become the
hief pathogens in HSCT [1]. Invasive fungal infec-
ion (IFI) has become a frequent complication ofaHisamaru Hirai died in August 2003.
B&MTSCT, and Aspergillus species are the most common
ausative organisms [2]. The reported incidence of
nvasive aspergillosis (IA) after HSCT has been 6.3%
o 15.1% [3,4]. Reported risk factors for IA include
eutropenia, transplantation without laminar air ﬂow
quipment, transplantation from a matched unrelated
onor, presence of graft-versus-host disease (GVHD),
se of corticosteroids, older age, and underlying dis-
ases [3,4]. Routine screening with high-resolution
hest computed tomography scanning [5] and the de-
elopment of non–culture-based diagnostic methods
6,7] have improved our ability to diagnose IA. Fur-
hermore, new investigational agents with impressive
ctivity against Aspergillus species have also been
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6hown to be useful in early clinical trials [8,9]. Despite
hese advances in diagnostic and treatment modalities
or IA [5-7], its prognosis still remains poor, with high
ortality rates ranging from 50% to 90% [3,4,10].
Reduced-intensity HSCT (RIST) is a new trans-
lantation strategy that was developed to decrease
egimen-related toxicity while preserving an adequate
ntitumor effect [11]. Different pioneering condition-
ng regimens for RIST have been investigated, includ-
ng a combination of purine analogs [12] and total
ody irradiation with potent immunosuppressants
13]. It is assumed that elderly patients, who are not
ligible for conventional stem cell transplantation
CST) with a myeloablative regimen, may be able to
eneﬁt from RIST. Favorable results have been re-
orted in patients with various hematologic malignan-
ies, including chronic myelocytic leukemia [14] and
alignant lymphoma [15]. Among solid tumors, met-
static renal cell carcinoma has been shown to respond
ell to RIST [16], and on the basis of these early
linical results, studies are currently under way to
valuate the efﬁcacy of RIST in a wide variety of
ematologic and nonhematologic malignancies.
However, it remains unknown whether RIST car-
ies the same risk of IA, because it is associated with a
horter neutropenic period and less regimen-related
oxicity. Several studies have suggested that IA still
ccurs frequently after RIST [17,18], whereas others
ave reported no increase in IFIs despite an increase
n the rate of cytomegalovirus (CMV) infection [19].
ll of these studies on IA after RIST were small, with
2 to 163 patients, and there is still only limited
nformation on this complication. In this study, we
nvestigated the clinical characteristics of IA after
IST, with regard to its incidence, characteristics, and
isk factors, in comparison to those after CST.
ATIENTS AND METHODS
atients
The medical records of all of the patients who
nderwent allogeneic HSCT at the National Cancer
enter Hospital, Toranomon Hospital, Tokyo Met-
opolitan Komagome Hospital, and the University of
okyo Hospital between January 1999 and November
002 were reviewed. Among the 664 patients, 486
nderwent CST and 178 underwent RIST (Table 1).
he patients in the RIST group were signiﬁcantly
lder, and their malignancies were in more advanced
tages than those in the CST group (P  .01 and P 
01, respectively). The 3-year non-IA mortality rates
fter CST and RIST were 41.2% and 50.2%, respec-
ively (P  .24).
The factors that we considered to be associated
ith low risk for transplantation were as follows: acute
yeloblastic leukemia or acute lymphoblastic leuke-
46ia in ﬁrst or second complete remission, chronic
yelogenous leukemia in chronic phase, and myelo-
ysplastic syndrome refractory anemia. All other pa-
ients were deﬁned as having high-risk diseases. All of
he patients with solid tumors were incurable with
onventional treatments.
tem Cell Sources
In the CST group, 423 and 63 patients received
ransplants from an HLA-identical and 1 antigen–
ismatched donor, respectively (Table 1). In the CST
roup, 96 patients received granulocyte colony-stim-
lating factor–mobilized peripheral blood stem cells,
hereas 390 received bone marrow. In the RIST
roup, 153 patients had an HLA-identical donor and
5 had a mismatched donor, and the stem cell source
as peripheral blood (n  155) or bone marrow (n 
3).
reparative Regimens
Conventional preparative regimens consisted of
yclophosphamide (CY) and total body irradiation
n  295) or of busulfan and CY (n  191), as shown
n Table 1. Reduced-intensity preparative regimens
ncluded ﬂudarabine/CY-based (n  21), ﬂudarabine/
usulfan-based (n  119), ﬂudarabine/melphalan-
ased (n  13), and cladribine/busulfan-based regi-
ens (n  25). Antithymocyte globulin was added to
he preparative regimen in 7 CST and 74 RIST pa-
ients. Total body irradiation (4 to 8 Gy) was further
dded in 14 RIST patients.
rophylaxis and Treatment of GVHD
Cyclosporine (CSP) and short-term methotrexate
ere primarily used for GVHD prophylaxis in the
ST group (Table 1), whereas most of the RIST
atients received CSP 3 mg/kg alone. The diagnosis
f GVHD was clinically made in concert with biopsy
f the skin or gastrointestinal tract. Acute and chronic
VHD were graded according to the consensus cri-
eria [20,21]. Grade II to IV acute GVHD was treated
ith methylprednisolone 2 mg/kg/d in addition to
SP.
anagement of Infections
Most of the patients were cared for in reverse
solation in a laminar airﬂow-equipped room, and they
eceived prophylaxis with trimethoprim/sulfamethox-
zole or pentamidine inhaler and ciproﬂoxacin against
neumocystis carinii and bacterial infection, respec-
ively. Herpesvirus prophylaxis with acyclovir was also
iven as previously described [22]. CMV pp65 anti-
enemia was routinely monitored once a week. When
ntigenemia was detected, preemptive therapy with
anciclovir was initiated as previously reported [22].
Absorbable antifungal agents, usually ﬂuconazole,
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Invasive Aspergillosis after RIST
Bere used for antifungal prophylaxis at a dose ranging
rom 200 to 400 mg/d. Neutropenic fever was treated
ccording to the recommendation of Pizzo [23].
rieﬂy, we empirically started both a -lactam antibi-
tic and an aminoglycoside at the time of the ﬁrst
ebrile episode. Intravenous administration of ampho-
ericin B at 0.5 mg/kg/d was added when the fever
ersisted for more than 5 to 7 days. If the diagnosis of
spergillus infection was conﬁrmed, the dosage of am-
hotericin B was increased to 1.0 mg/kg/d. We used
lood tests, enzyme-linked immunosorbent assay for
alactomannan antigen, (1-3)-beta-d-glucan assay,
nd chest computed tomography for the early diagno-
is of IA, as previously reported [5].
iagnostic Criteria for IA
IA was categorized as proven, probable, or possi-
le IA, according to the established European Orga-
ization for Research and Treatment of Cancer
EORTC)/National Institutes of Health (NIH)/My-
able 1. Characteristics of Patients
Variable CS
ge, y, median (range)
ex (male/female)
nderlying diseases
Acute myeloid leukemia
Acute lymphoblastic leukemia
Chronic myelogenous leukemia
Myelodysplastic syndrome
Malignant lymphoma
Solid tumors*
Others
isk for transplantation (low/high)†
tem cells (peripheral blood/bone marrow)
LA (matched/mismatched)
onor (related/unrelated)
onditioning regimen
TBI/CY-based
BU/CY-based
2-CdA/BU-based
Flu/BU-based
Flu/CY
Flu/Mel
VHD prophylaxis
CSP
CSP MTX
FK506
FK506 sMTX
Others
ST indicates conventional stem cell transplantation; RIST, redu
cyclophosphamide; BU, busulfan; 2-CdA, cladribine; Flu, ﬂudar
ate.
All the patients with solid tumors had documented progressive les
We divided the risk of transplantation into 2 groups. The low-ris
second remission, chronic myelogenous leukemia in chronic ph
were deﬁned as having high-risk diseases.
Four patients were infused with both peripheral and bone marrowology Study Group (MSG) criteria [24]. Brieﬂy, we C
B&MTiagnosed patients as having proven IA when there
as histologic evidence of tissue invasion by small
niform, dichotomously branching hyphae, septate at
egular intervals, and/or culture ﬁndings positive for
spergillus species from autopsy specimens, mostly the
ung, and a compatible clinical presentation. Probable
A was deﬁned as radiographic ﬁndings compatible
ith IA on computed tomography with clinical symp-
oms and positive ﬁndings in enzyme-linked immu-
osorbent assay for galactomannan antigen. Aspergil-
us antigen positivity was deﬁned as an optical density
ndex of galactomannan 1.5 in 2 consecutive blood
amples by an enzyme-linked immunosorbent assay
Platelia Aspergillus EIA; Bio-Rad Laboratories, Her-
ules, CA). Possible IA was not included in this study.
nd Points and Statistical Analysis
The primary end point of this study was the inci-
ence of IA after allogeneic HSCT, and the probabil-
ty of IA after RIST was compared with that after
486) RIST (n  178) P Value
8) 53 (4-70) <.01
110/68 .67
44 <.01
5
12
27
36
34
20
55/123 <.01
‡ 155/23 <.01
153/25 .72
154/24 <.01
25
119
21
13
118
57
0
0
3
ensity stem cell transplantation; TBI, total body irradiation; CY,
el, melpharan; CSP, cyclosporine; sMTX, short-term methotrex-
spite prior therapy.
p was as follows: acute myeloid or lymphoid leukemia in ﬁrst and
d myelodysplastic syndrome refractory anemia. The other patients
e patients were assigned to the bone marrow group.T (n 
36 (1-5
309/177
154
111
129
43
31
0
18
290/196
96/390
423/63
224/262
295
191
9
426
3
46
2
ced-int
abine; M
ions de
k grou
ase, an
. ThesST. Another objective was to investigate the char-
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6cteristics and risk factors of IA. The cumulative in-
idence curves of IA were produced by using Gray’s
ethod [25], considering death without IA as a com-
eting risk. The median follow-up period after trans-
lantation was 518 days (range, 2-1874 days), and
urviving patients were censored on the last day of
ollow-up.
Risk factors associated with IA were identiﬁed in
nivariate and multivariate Cox regression models.
he variables analyzed included age, sex, primary dis-
ase and its status at transplantation, stem cell source,
onor type, and type of transplantation (CST versus
IST). To evaluate the inﬂuence of the development
f grade II to IV acute or chronic GVHD, propor-
ional hazard modeling was used, with the onset of
VHD treated as a time-dependent covariate. Vari-
bles with a P value of .10 were subjected to a
ultivariate analysis with backward stepwise propor-
ional hazard modeling. P values .05 were consid-
red signiﬁcant.
ESULTS
ncidence of IA
Thirty-ﬁve (5.6%) patients were diagnosed as hav-
ng IA, which gave a 3-year cumulative incidence of
.9%. Five of the 35 cases had proven IA, and the
emaining 30 had probable IA according to the
ORTC/NIH/MSG criteria [24]. The diagnosis of IA
as established after death in 4 of the 5 patients with
roven IA, and 1 of these cases was diagnosed with a
able 2. Clinical Characteristics of Patients with Invasive Aspergillosis
Variable
ge, y, median (range)
ntifungal prophylaxis, fluconazole/others
ulmonary complication before HSCT, yes/no
isk of transplantation†, low/high
eutropenia at onset of IA, yes/no
raft-versus-host disease (GVHD), acute/chronic/none
se of corticosteroid‡, yes/no
MV infection (antigenemia positive), yes/no
nset day of invasive aspergillosis, median (range)
reatment
deoxycholate amphotericin B
liposomal amphotericin B
itraconazole
no treatment
esponse to antifungal therapy, yes/no
ortality after IA diagnosis, within 30 days
ST indicates conventional stem cell transplantation, RIST indica
alovirus.
Statistically signiﬁcant.
We divided the risk of transplantation into 2 groups. The low-ris
second remission, and myelodysplastic syndrome. The other pa
Use of corticosteroid during administration of antithymocyte globransbronchial lung biopsy. Three of the remaining 4 r
48roven cases had been diagnosed as probable IA while
he patients were alive. The day of diagnosis of IA was
eﬁned as the day when the ﬁrst diagnostic test was
erformed. Thirty patients were diagnosed as having
robable IA on the basis of clinical, radiologic, and
icrobiological ﬁndings. All the patients showed
ome subjective or objective symptoms. The circulat-
ng galactomannan antigen assay tested positive in 26
atients. Aspergillus species were cultured from spu-
um in 3 patients, and bronchoalveolar lavage ﬂuid
as positive for galactomannan antigen in a patient.
ll of the 30 patients underwent chest computed to-
ography scan, and all of them showed some abnor-
al ﬁndings including halo and multiple nodules.
linical Characteristics of IA
The clinical characteristics of patients with IA are
hown in Table 2. All cases developed after engraft-
ent, whereas 3 patients each in the RIST and CST
roups were still neutropenic at the presentation of
A. The median time to the onset after RIST (127
ays) was later than that after CST (97 days; P  .01).
ll of the patients had been receiving ﬂuconazole
rophylaxis when the diagnosis of IA was established.
f the 35 patients with IA, 30 (86%) had GVHD
acute in 16 and chronic in 14). Thirty patients had
een receiving corticosteroid treatment at the time of
A diagnosis, all for the treatment of GVHD. CMV
ntigenemia was positive in 9 of the 35 patients, and 3
f these progressed to CMV disease. Five patients
ith IA showed no signs of GVHD and were not
ST (n  21) RIST (n  14) P value
8 (22-57) 54 (37-70) <.01*
21/0 14/0
2/19 1/13 1.00
7/14 2/12 .26
3/18 3/11 .66
11/7/3 5/7/2
17/4 13/1 .63
4/17 5/9 .43
7 (11-885) 127 (35-364) <.01
14 10 .67
2 1
5 2
0 1
6/15 5/9 .72
7 8 .19
uced-intensity stem cell transplantation, CMV indicates cytomeg-
p was as follows: acute myeloid or lymphoid leukemia in ﬁrst and
ere deﬁned as having high-risk diseases.
as excluded from this analysis.C
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Invasive Aspergillosis after RIST
Bf IA was established. The clinical characteristics of
atients with IA after RIST (n  14) were compared
ith those with IA after CST (n 21), as summarized
n Table 2. Except for age and onset of IA, no signif-
cant differences were observed between groups.
reatment and Outcomes
Initial antifungal treatment consisted of deoxy-
holate amphotericin B (n  24), liposomal ampho-
ericin B (n  3), and itraconazole (n  7). One
atient did not receive any antiaspergillus treatment
ecause the diagnosis of IA was established after
eath. Sixteen (76%) of the 21 CST recipients and 12
86%) of the 14 RIST recipients who developed IA
ied, and IA was the direct cause of death in 5 patients
n each group. The 1-year survival rates after the
iagnosis of IA were similarly poor in both groups
24% versus 19%; P  .19; Figure 1).
isk Factors for IA
The actuarial frequency for the development of IA
n the RIST group was 7.9% (14/178), which gave a
-year cumulative incidence of 8.2%. In the CST
roup, 21 (4.3%) of 487 patients developed IA, to give
3-year cumulative incidence of 4.5%. The probabil-
ty of developing IA was signiﬁcantly higher in the
IST group than in the CST group (P  .045; Figure
). Old age (P  .0068), disease risk for transplanta-
ion (P  .0043), RIST (P  .045), and the develop-
ent of GVHD (P  .00014) were signiﬁcant risk
actors for IA by univariate analysis (Table 3). Among
hese factors, only age50 years and the development
f GVHD were conﬁrmed to be independently sig-
iﬁcant by proportional hazard models (Table 3). The
ifference in the types of preparative regimens was not
igure 1. Overall survival after the diagnosis of IA. The survival
ate at 1 year after the diagnosis of IA was similarly poor in both the
IST and CST groups (27% and 18%, respectively; P  .24).igniﬁcant after adjusting for age, donor sources, and c
B&MThe development of GVHD (RIST: relative risk, 1.52;
5% conﬁdence interval, 0.64-3.6; P  .34).
ISCUSSION
This study was conducted to investigate the inci-
ence and clinical features of IA after RIST compared
ith those after CST. IA is a signiﬁcant complication
n patients receiving CST, but little information is
urrently available on IA after RIST. Although the
etrospective nature of this study is a limitation, this is
ne of the largest studies on IA after RIST and pro-
ides valuable information on this complication. We
ound that the incidence of IA was 4.3% and 7.9% in
ST and RIST recipients, respectively. IA tended to
e more common in older patients after RIST than
fter CST, suggesting that IA is still a signiﬁcant
omplication in RIST, as well as in CST, in this
etting. The incidence of IA in our study is lower than
hose in previous reports after CST [4] or RIST [18].
lthough the reason for this difference is unclear, it
ight be associated with the lower incidence of
VHD and the consequent decrease in the use of
teroids in our country [26]: both of these are known
isk factors for IA [4].
The diagnostic criteria used in epidemiologic
tudies on IA are debatable. IA is difﬁcult to diagnose
hile patients are alive, and it is frequently conﬁrmed
y autopsy. We strictly applied the diagnostic criteria
ecommended by EORTC/NIH/MSG [24]. How-
ver, in retrospective epidemiologic studies, the num-
er of “IA” cases depends on whether both possible
nd probable IA cases are included. Because we in-
luded only probable and proven cases in this study
nd excluded possible cases, the rate of IA might have
een underestimated. Nevertheless, we believe that
he primary end point was achieved, because we com-
igure 2. The incidences of invasive aspergillosis after RIST and
ST. The cumulative incidences of IA at 3 years after RIST and
ST were 8.2% and 4.5%, respectively, with a statistically signiﬁ-
ant difference (P  .045).
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6ared the 2 groups of patients by using the same
riteria.
The onset of IA is bimodal, peaking 16 and 96
ays after transplantation [3]. Recent studies, includ-
ng ours, have shown that the development of IA has
hifted to a late onset [4,18]. Several factors have
ontributed to the shift of IA development. First, most
ecipients undergo transplantation in a laminar air
ow–equipped room with or without high-efﬁciency
articulate air ﬁlters, which have been demonstrated
o be protective against aspergillus infection [3]. Sec-
nd, early-onset IA tends to occur among patients
ith incubating or occult aspergillus infection, and
hese high-risk patients usually receive some anti-
spergillus agents before or immediately after trans-
lantation. Third, the development of GVHD, which
requently necessitates corticosteroid therapy, is de-
ayed in RIST compared with CST [27]. Both GVHD
nd the use of corticosteroids are independent risk
actors for IA after HSCT [4]. Finally, the develop-
ent of CMV infection, which is associated with IA
28], is also delayed in RIST [29]. We should there-
ore recognize that IA has been well characterized as a
ate-onset complication in RIST, and any preventive
trategy for IA should be extended to cover the pos-
ibility of late aspergillosis. Prolonged prophylaxis
ith antiaspergillus agents such as voriconazole and
traconazole might be beneﬁcial for reducing its inci-
able 3. Risk Factors for Invasive Aspergillosis
Factor Variable
nivariate analysis
retransplant factors
Sex Male
Female
Age <50
>50
Risk for transplantation High-risk
Low-risk
Donor Matched related
Mismatched related
Matched unrelated
Mismatched unrela
Graft source Bone marrow
Peripheral Blood
Preparative regimen Conventional
Reduced-intensity
Use of ATG With
Without
osttransplant factor
GVHD (acute and/or chronic) Presence vs Absenc
Factor Relative Risk
ultivariate analysis
Age older than 50 2.12
GVHD (acute and/or chronic) 6.2
TG indicates Antithymocyte globin; GVHD indicates graft-versu
Statistically signiﬁcant.ence. a
50We found that IA is associated with a poor prog-
osis in RIST as well as in CST. In this study, only 2
f the 14 RIST recipients and 5 of the 21 CST
ecipients who developed IA survived. Although most
atients with IA had been intensively treated with
ntravenous amphotericin B, the response rate to
reatment was only 36% and 29% in RIST and CST
ecipients, respectively. Despite the recent availability
f new antifungal agents such as voriconazole, itra-
onazole, and lipid-complex amphotericin B prepara-
ions, treatment of IA in recipients of HSCT is still a
ifﬁcult task without the recovery of host immunity.
It is important to determine the risk factors of IA
o identify high-risk patients and to enable the intro-
uction of prophylaxis for more intense infection. The
rimary risk factor for IA in our study was the devel-
pment of GVHD and the closely associated use of
orticosteroid, because they further delay immune re-
overy to open the way for the development of IA.
ecause the incidence of GVHD after RIST is similar
o that after CST in this study, it is quite reasonable
hat the clinical signiﬁcance of IA is comparable to
hat after CST. Although use of antithymocyte glob-
lin might be associated with an increase in the risk of
FI, this was not observed in our study. We speculate
hat the decrease in the incidence of GVHD with the
ntroduction of antithymocyte globulin (10% in this
tudy) contributed to the decrease in the use of steroid
n Incidences P value
419 5.9% .48
245 4.9%
471 4.1% .0068*
193 9.2%
486 7.2% .0043*
178 3.9%
343 5.6% .39
39 11.7%
233 4.7%
49 4.1%
413 4.1% .091
251 7.8%
486 4.5% .045*
178 8.2%
81 5.4% .91
583 5.6%
6.55 (2.49-17.2) .00014*
95% Confidence interval P value
1.08-4.17 .03*
2.4-16.4 .0002*
disease.ted
e
s-hostnd, hence, decreased the risk of IA. Because the dose
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Invasive Aspergillosis after RIST
Bf antithymocyte globulin we used was lower than
hose used in other institutes [12,30], the mild sup-
ression of immune recovery might be another reason
or the lower incidence of IA.
We believe that this study will provide some useful
nformation on IA; however, there are several limita-
ions. We compared the incidence of IA between the
treatment groups. They had different backgrounds,
nd many different preparative regimens were used
or different underlying diseases, thus making it difﬁ-
ult to draw deﬁnite conclusion on IA from this study.
he reliability of patient diagnosis is another concern.
lthough we made an IA diagnosis by using the
ORTC/NIH/MSG criteria [24], only 1 of 7 IA pa-
ients had histopathologic evidence of IA. The
ORTC/NIH/MSG criteria are the best currently
vailable consensus on IFI in immunocompromised
atients. However, it is well known that it is difﬁcult
o make an accurate diagnosis of IA in recipients of
llogeneic HSCT, and most cases are diagnosed by
ostmortem examination. Additionally, the retrospec-
ive nature of this study provides a potential bias.
evelopment of IA is associated with GVHD and
orticosteroid use. Further study is required to inves-
igate the association between IA development and
ther variables, including the severity of GVHD and
he dose and duration of corticosteroid use. A pro-
pective evaluation is warranted to further clarify the
linical features of IA after RIST.
In conclusion, we showed that IA is a major com-
lication of RIST that affects older patients and is
ssociated with signiﬁcant mortality. Special attention
hould be paid to the effect of steroid treatment on
omplicated GVHD, especially in older patients. Cur-
ently, high-efﬁciency particulate air ﬁlters and cor-
ectly sealed rooms are accepted as proper prophylaxis
or IA. However, these measures are not realistic in
IST, in which the onset of IA averaged beyond 100
ays, when patients are generally followed up in the
utpatient clinic [31]. The effectiveness of chemopro-
hylaxis with newly developed drugs against aspergil-
us [32,33] and of changing the home environment to
liminate the routes of infection for aspergillosis
hould be seriously investigated.
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